DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 197 filers reported holding DENALI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,172,400 | -42.7% | 154,000 | -18.1% | 1.07% | -36.6% |
| Q2 2023 | $5,538,480 | +177.7% | 188,000 | +117.2% | 1.69% | +202.7% |
| Q1 2023 | $1,994,688 | +88.9% | 86,575 | +127.8% | 0.56% | +70.9% |
| Q4 2022 | $1,056,020 | -9.4% | 38,000 | 0.0% | 0.33% | -12.8% |
| Q3 2022 | $1,166,000 | -96.9% | 38,000 | +3298.9% | 0.37% | -5.6% |
| Q2 2022 | $38,000,000 | +363.9% | 1,118 | -97.1% | 0.40% | -78.6% |
| Q1 2022 | $8,192,000 | +607.4% | 38,000 | +46.2% | 1.85% | +615.9% |
| Q4 2021 | $1,158,000 | – | 26,000 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |